Efficacy and safety of nirsevimab for preventing respiratory syncytial virus infection in infants: an updated systematic review and meta-analysis encompassing 11,001 participants.

Q3 Medicine

Baylor University Medical Center Proceedings Pub Date : 2025-04-16 eCollection Date: 2025-01-01 DOI:10.1080/08998280.2025.2488211

Mohammad Tanashat, Mohamed Abuelazm, Almothana Manasrah, Obieda Altobaishat, Noor M Masadeh, Mohamed Abouzid

{"title":"Efficacy and safety of nirsevimab for preventing respiratory syncytial virus infection in infants: an updated systematic review and meta-analysis encompassing 11,001 participants.","authors":"Mohammad Tanashat, Mohamed Abuelazm, Almothana Manasrah, Obieda Altobaishat, Noor M Masadeh, Mohamed Abouzid","doi":"10.1080/08998280.2025.2488211","DOIUrl":null,"url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is recognized as the leading cause of lower respiratory tract infections (LRTI) and a major contributor to newborn hospitalizations. Recent clinical trials have demonstrated the effectiveness of nirsevimab in preventing RSV infections among infants. This meta-analysis evaluated the efficacy and safety of nirsevimab in healthy infants born at varying gestational ages during their first RSV season.Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched electronic databases-PubMed, SCOPUS, Cochrane Library, and Web of Science-to identify relevant studies published up to March 2025.Results: We included three studies with 11,001 participants. Nirsevimab was significantly associated with decreased hospitalization for LRTI due to RSV (risk ratio [RR]: 0.21; 95% confidence interval [CI] 0.13, 0.33; P = 0.00001), hospitalization for respiratory illness due to any cause (RR: 0.46; 95% CI 0.36, 0.59; P = 0.00001), and medically attended RSV-associated LRTI (RR: 0.25; 95% CI 0.18, 0.36; P = 0.00001) compared to placebo. Comparable results were found in composite safety outcomes and adverse events; however, nirsevimab significantly reduced the incidence of bronchiolitis (RR: 0.70; 95% CI 0.56, 0.88; P = 0.002).Conclusion: Nirsevimab shows promise in preventing RSV infections and hospitalizations, warranting further study on its practicality and cost-effectiveness.","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 4","pages":"524-534"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2025.2488211","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Respiratory syncytial virus (RSV) is recognized as the leading cause of lower respiratory tract infections (LRTI) and a major contributor to newborn hospitalizations. Recent clinical trials have demonstrated the effectiveness of nirsevimab in preventing RSV infections among infants. This meta-analysis evaluated the efficacy and safety of nirsevimab in healthy infants born at varying gestational ages during their first RSV season.

Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched electronic databases-PubMed, SCOPUS, Cochrane Library, and Web of Science-to identify relevant studies published up to March 2025.

Results: We included three studies with 11,001 participants. Nirsevimab was significantly associated with decreased hospitalization for LRTI due to RSV (risk ratio [RR]: 0.21; 95% confidence interval [CI] 0.13, 0.33; P = 0.00001), hospitalization for respiratory illness due to any cause (RR: 0.46; 95% CI 0.36, 0.59; P = 0.00001), and medically attended RSV-associated LRTI (RR: 0.25; 95% CI 0.18, 0.36; P = 0.00001) compared to placebo. Comparable results were found in composite safety outcomes and adverse events; however, nirsevimab significantly reduced the incidence of bronchiolitis (RR: 0.70; 95% CI 0.56, 0.88; P = 0.002).

Conclusion: Nirsevimab shows promise in preventing RSV infections and hospitalizations, warranting further study on its practicality and cost-effectiveness.

查看原文本刊更多论文

尼瑟维单抗预防婴儿呼吸道合胞病毒感染的有效性和安全性：一项包含11,001名参与者的最新系统评价和荟萃分析

背景：呼吸道合胞病毒（RSV）被认为是下呼吸道感染（LRTI）的主要原因，也是新生儿住院的主要原因。最近的临床试验证明了尼瑟维单抗在预防婴儿呼吸道合胞病毒感染方面的有效性。本荟萃分析评估了在第一个RSV季节出生的不同胎龄的健康婴儿中使用nirseimab的有效性和安全性。方法：根据系统评价和荟萃分析的首选报告项目（PRISMA）指南，我们检索了pubmed、SCOPUS、Cochrane Library和Web of science等电子数据库，以确定截至2025年3月发表的相关研究。结果：我们纳入了3项研究，11,001名参与者。nirseimab与RSV所致下呼吸道感染住院率降低显著相关(风险比[RR]: 0.21；95%置信区间[CI] 0.13, 0.33；P = 0.00001)，任何原因导致的呼吸系统疾病住院(RR: 0.46；95% ci 0.36, 0.59；P = 0.00001)，就诊的rsv相关LRTI (RR: 0.25；95% ci 0.18, 0.36；P = 0.00001)。在综合安全结局和不良事件中发现了类似的结果；然而，nirsevimab显著降低了毛细支气管炎的发病率(RR: 0.70；95% ci 0.56, 0.88；p = 0.002)。结论：Nirsevimab在预防RSV感染和住院治疗方面具有良好的前景，值得进一步研究其实用性和成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Baylor University Medical Center Proceedings Medicine-Medicine (all)

CiteScore

1.30

自引率

0.00%

发文量

245